Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 25

1.

Engineered botulinum neurotoxin B with improved binding to human receptors has enhanced efficacy in preclinical models.

Elliott M, Favre-Guilmard C, Liu SM, Maignel J, Masuyer G, Beard M, Boone C, Carré D, Kalinichev M, Lezmi S, Mir I, Nicoleau C, Palan S, Perier C, Raban E, Zhang S, Dong M, Stenmark P, Krupp J.

Sci Adv. 2019 Jan 16;5(1):eaau7196. doi: 10.1126/sciadv.aau7196. eCollection 2019 Jan.

2.

LRRK2 impairs PINK1/Parkin-dependent mitophagy via its kinase activity: pathologic insights into Parkinson's disease.

Bonello F, Hassoun SM, Mouton-Liger F, Shin YS, Muscat A, Tesson C, Lesage S, Beart PM, Brice A, Krupp J, Corvol JC, Corti O.

Hum Mol Genet. 2019 Jan 9. doi: 10.1093/hmg/ddz004. [Epub ahead of print]

PMID:
30629163
3.

A comparison of biological activity of commercially available purified native botulinum neurotoxin serotypes A1 to F1 in vitro, ex vivo, and in vivo.

Donald S, Elliott M, Gray B, Hornby F, Lewandowska A, Marlin S, Favre-Guilmard C, Périer C, Cornet S, Kalinichev M, Krupp J, Fonfria E.

Pharmacol Res Perspect. 2018 Nov 22;6(6):e00446. doi: 10.1002/prp2.446. eCollection 2018 Dec.

4.

Engineering Botulinum Toxins to Improve and Expand Targeting and SNARE Cleavage Activity.

Fonfria E, Elliott M, Beard M, Chaddock JA, Krupp J.

Toxins (Basel). 2018 Jul 4;10(7). pii: E278. doi: 10.3390/toxins10070278. Review.

5.

The Expanding Therapeutic Utility of Botulinum Neurotoxins.

Fonfria E, Maignel J, Lezmi S, Martin V, Splevins A, Shubber S, Kalinichev M, Foster K, Picaut P, Krupp J.

Toxins (Basel). 2018 May 18;10(5). pii: E208. doi: 10.3390/toxins10050208. Review.

6.

Augmentation of VAMP-catalytic activity of botulinum neurotoxin serotype B does not result in increased potency in physiological systems.

Elliott M, Maignel J, Liu SM, Favre-Guilmard C, Mir I, Farrow P, Hornby F, Marlin S, Palan S, Beard M, Krupp J.

PLoS One. 2017 Oct 5;12(10):e0185628. doi: 10.1371/journal.pone.0185628. eCollection 2017.

7.

Engineered botulinum neurotoxin B with improved efficacy for targeting human receptors.

Tao L, Peng L, Berntsson RP, Liu SM, Park S, Yu F, Boone C, Palan S, Beard M, Chabrier PE, Stenmark P, Krupp J, Dong M.

Nat Commun. 2017 Jul 3;8(1):53. doi: 10.1038/s41467-017-00064-y.

8.

Botulinum Neurotoxins Serotypes A and B induce paralysis of mouse striated and smooth muscles with different potencies.

Maignel-Ludop J, Huchet M, Krupp J.

Pharmacol Res Perspect. 2017 Jan 31;5(1):e00289. doi: 10.1002/prp2.289. eCollection 2017 Feb.

9.

SCN10A Mutation in a Patient with Erythromelalgia Enhances C-Fiber Activity Dependent Slowing.

Kist AM, Sagafos D, Rush AM, Neacsu C, Eberhardt E, Schmidt R, Lunden LK, Ørstavik K, Kaluza L, Meents J, Zhang Z, Carr TH, Salter H, Malinowsky D, Wollberg P, Krupp J, Kleggetveit IP, Schmelz M, Jørum E, Lampert A, Namer B.

PLoS One. 2016 Sep 6;11(9):e0161789. doi: 10.1371/journal.pone.0161789. eCollection 2016.

10.

Propofol and AZD3043 Inhibit Adult Muscle and Neuronal Nicotinic Acetylcholine Receptors Expressed in Xenopus Oocytes.

Jonsson Fagerlund M, Krupp J, Dabrowski MA.

Pharmaceuticals (Basel). 2016 Feb 6;9(1). pii: E8. doi: 10.3390/ph9010008.

11.

Reduced efficacy of the intravenous anesthetic agent AZD3043 at GABA(A) receptors with β2 (N289M) and β3 (N290M) point-mutations.

Jonsson Fagerlund M, Sjödin J, Dabrowski MA, Krupp J.

Eur J Pharmacol. 2012 Nov 5;694(1-3):13-9. doi: 10.1016/j.ejphar.2012.07.040. Epub 2012 Aug 23.

PMID:
23009769
12.

Linkage analysis and functional evaluation of inherited clinical pain conditions.

Krupp JJ, Hellgren D, Eriksson AB.

Methods Mol Biol. 2010;617:309-25. doi: 10.1007/978-1-60327-323-7_23.

PMID:
20336431
13.

Voltage-gated sodium channels in neurological disorders.

Chahine M, Chatelier A, Babich O, Krupp JJ.

CNS Neurol Disord Drug Targets. 2008 Apr;7(2):144-58. Review.

PMID:
18537643
14.

Ion channel screening technology.

Dabrowski MA, Dekermendjian K, Lund PE, Krupp JJ, Sinclair J, Larsson O.

CNS Neurol Disord Drug Targets. 2008 Apr;7(2):122-8. Review.

PMID:
18537641
15.

Role of ion channels in neurological disorders.

Krupp JJ.

CNS Neurol Disord Drug Targets. 2008 Apr;7(2):120-1. No abstract available.

PMID:
18537640
16.

Biophysical properties of human Na v1.7 splice variants and their regulation by protein kinase A.

Chatelier A, Dahllund L, Eriksson A, Krupp J, Chahine M.

J Neurophysiol. 2008 May;99(5):2241-50. doi: 10.1152/jn.01350.2007. Epub 2008 Mar 12.

17.

Cellular HTS assays for pharmacological characterization of Na(V)1.7 modulators.

Trivedi S, Dekermendjian K, Julien R, Huang J, Lund PE, Krupp J, Kronqvist R, Larsson O, Bostwick R.

Assay Drug Dev Technol. 2008 Apr;6(2):167-79.

PMID:
18078380
18.

Distribution of the voltage-gated sodium channel Na(v)1.7 in the rat: expression in the autonomic and endocrine systems.

Morinville A, Fundin B, Meury L, Juréus A, Sandberg K, Krupp J, Ahmad S, O'Donnell D.

J Comp Neurol. 2007 Oct 20;504(6):680-9.

PMID:
17722032
19.

A stop codon mutation in SCN9A causes lack of pain sensation.

Ahmad S, Dahllund L, Eriksson AB, Hellgren D, Karlsson U, Lund PE, Meijer IA, Meury L, Mills T, Moody A, Morinville A, Morten J, O'donnell D, Raynoschek C, Salter H, Rouleau GA, Krupp JJ.

Hum Mol Genet. 2007 Sep 1;16(17):2114-21. Epub 2007 Jun 27.

PMID:
17597096
20.

N-methyl-D-aspartate receptor (NMDA) antagonists as potential pain therapeutics.

Brown DG, Krupp JJ.

Curr Top Med Chem. 2006;6(8):749-70. Review.

PMID:
16719815

Supplemental Content

Loading ...
Support Center